Conventional therapies for autoimmune conditions involve some combination of immune suppressive therapies.  In contrast, the LRA (Lymphocyte Response Assay) by ELISA/ACT™ is a way of determining for each individual what items are burdening the immune system and a system for restoring immune competence.

The LRA tests measure all three delayed allergy pathways while avoiding false positives common in other types of delayed allergy tests.  :

• Reactive antibody (IgA, IgM, and IgG)

• Immune complexes

• Direct T-cell activation

Identifying the patient’s specific sensitivities and delayed allergies that burden the immune system is a clinical breakthrough.  Patients often experience a dramatic improvement in the quality of their life as a result of the individualized treatment plan.  After six months, a reevaluation of progress is recommended with 3 possible outcomes.

1). If patient is in full remission a guided gradual reintroduction of previously reactive items is advised

2). If patient is better but not yet well, repeat LRA tests.  Since digestion, among other systems, takes time to recover, it is common for people to lose some reactive items and acquire new ones.  A repeat program starting from a healthier base is likely to further improve health and sustain remission.

3). If patient reports following instructions carefully and avoiding reactive items but is still not better, look for toxins that might serve as inhibitors to recovery.  If a person reports making best efforts at following the program and does not report improvement, repeat testing is not indicated.

Healthy immune tolerance means no LRA reactions.